4DE Stock Overview
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BiVictriX Therapeutics Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.13 |
| 52 Week High | UK£0.16 |
| 52 Week Low | UK£0.10 |
| Beta | -0.61 |
| 1 Month Change | 4.13% |
| 3 Month Change | -0.79% |
| 1 Year Change | -20.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4DE | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.2% | 2.0% |
| 1Y | -20.3% | -25.4% | 5.9% |
Return vs Industry: 4DE exceeded the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 4DE underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 4DE volatility | |
|---|---|
| 4DE Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4DE has not had significant price volatility in the past 3 months.
Volatility Over Time: 4DE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 17 | Tiffany Thorn | www.bivictrix.com |
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours.
BiVictriX Therapeutics Plc Fundamentals Summary
| 4DE fundamental statistics | |
|---|---|
| Market cap | €11.04m |
| Earnings (TTM) | -€2.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.1x
P/E RatioIs 4DE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DE income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£2.33m |
| Earnings | -UK£2.33m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4DE perform over the long term?
See historical performance and comparison